Structure Therapeutics (GPCR) Q3 2026 earnings review
Structure Therapeutics advances two obesity pills, but trial costs double
Structure Therapeutics, a biotech firm developing weight-loss pills, started late-stage trials for its lead drug while its research bills doubled. Chief executive Raymond Stevens began enrolling up to 4,700 patients in the Phase 3 studies for aleniglipron after a 72-week study showed up to 16% weight loss. That progress pushed third-quarter research spending to $135 million and widened the net loss to $145 million.
| Research and development expense | $134.6M +128% from a year ago |
|---|---|
| Net loss | $144.8M $65.7M a year ago |
| Cash and short-term investments | $1.24B down $103M from last quarter |
| Cash runway outlook | Unchanged funds operations through 2028 |
⚖️ Verdict: 🟢 Bullish
The story got better because two obesity pills cleared clinical tests without serious side effects. Starting aleniglipron at a low dose kept patient dropouts below 5% over 72 weeks, and a second pill, ACCG-2671, lasted six days in the body. One caution: the $1.2 billion cash reserve covers operations through 2028, but by our math that leaves $138 million per quarter and excludes commercial manufacturing.
The question now is whether the cash pile can cover both the massive Phase 3 trials and early launch preparation through 2028. Either trial spending levels off after initial startup bills, or rising enrollment and commercial supply costs force the company to raise money earlier. Full-year 2027 spending plans and fourth-quarter cash burn will tell.
🐂 Bull Case
Lead Obesity Pill Sustains Weight Loss With Few Dropouts
Structure Therapeutics is testing aleniglipron, a daily weight-loss pill that targets the GLP-1 hormone receptor to reduce appetite. In August, the biotech group started its two Phase 3 ACCOMPLISH trials, which will enroll up to 4,700 patients to seek regulatory approval.
In September, the company reported 72-week results from an extension of its earlier Phase 2b ACCESS study. Patients on the highest dose of 180 mg lost an average of 16.2% of their body weight, with "no observed plateau in the two top dose groups". Starting patients on a tiny 2.5 mg dose kept "treatment discontinuation rates of less than 5% due to treatment-emergent adverse events".
Side effects like nausea often force patients to stop taking oral weight-loss drugs early. Because the low starting dose kept dropouts below 5% over 72 weeks while matching the 16.2% weight loss seen at 56 weeks, the Phase 3 trials have a proven dosing plan.
What to watch: topline results from the 12-week SWITCH trial in the fourth quarter of 2026. Strong weight maintenance in patients switching from approved injections to aleniglipron would support its use as a long-term maintenance pill.
Second Weight-Loss Drug Supports Weekly Dosing
Beyond GLP-1 pills, the drugmaker is developing ACCG-2671, an oral medicine that mimics amylin and calcitonin, two hormones that regulate hunger and metabolism. In September, Structure Therapeutics reported initial Phase 1 single-dose results in 31 healthy adults and began a 12-week multi-dose trial in patients with obesity.
The single-dose study showed no serious side effects and a half-life of about six days. Because the drug stays in the body that long, the 12-week study is testing both daily and once-weekly pills, as well as pairing the pill with an injectable GLP-1 drug.
What to watch: topline 12-week multi-dose results in the first half of 2027. Weight loss on the weekly schedule would give the San Francisco company a once-a-week pill to compete against daily rivals.
🐻 Bear Case
Cash Runway Excludes Commercial Preparation Costs
"We are developing our commercial readiness plans and see significant opportunity for aleniglipron in both initial weight loss and long-term weight loss maintenance," chief executive Raymond Stevens said. Last quarter, the biotech firm hired a commercial chief to build those plans.
At the same time, Structure Therapeutics expects its $1.24 billion in cash and short-term investments to fund operations through 2028. However, that forecast "excludes additional costs related to pre-commercialization activities including commercial manufacturing".
- Cash and short-term investments: $1.24 billion, down $102.7 million from last quarter by our math
- Quarterly cash limit through 2028: $137.8 million on average across the nine remaining quarters by our math
- Third-quarter net loss: $144.8 million, up 120.3% from a year ago
This gap matters because the company cannot prepare for a drug launch without paying for commercial supply and marketing setup. Because the current loss already exceeds the average quarterly cash limit, adding commercial manufacturing bills will shorten the runway before 2028.
What to watch: full-year 2027 expense or cash burn plans in the fourth-quarter report. Including commercial manufacturing costs in the budget would force the company to shorten its 2028 cash timeline or raise money.
Late-Stage Trials Double Research Spending
Starting the 4,700-patient Phase 3 program for aleniglipron pushed operating costs much higher in the third quarter. Total operating expenses reached $156.3 million, more than double the $73.8 million spent a year ago and up 31.8% from the second quarter by our math.
Research and development — the cost of running clinical trials and lab work — drove the increase, rising 128.1% from a year ago to $134.6 million. Research took up 86.1% of total operating expenses, up 6.1 percentage points from a year ago by our math, while general and administrative overhead rose 47.2% to $21.8 million.
What to watch: fourth-quarter research and development expenses. Another jump above $135 million as Phase 3 enrollment expands would accelerate cash burn in 2027.
Oral Combination Trial Slips to Next Year
Stevens wants to pair the company's amylin and GLP-1 pills together to address different patient needs. In the second quarter, Structure Therapeutics planned to start a clinical trial combining aleniglipron and ACCG-2671 in the fourth quarter of 2026.
The drugmaker now expects to start that oral combination study in 2027. While the delay is short, it pushes back early human data on whether the two pills work safely together until after the standalone ACCG-2671 trial finishes.
What to watch: the exact start date of the oral combination trial in 2027. A delay beyond the first half of 2027 would slow the company's plan to offer a combined weight-loss pill.
👓 Other Themes
Three Supplementary Trials Will Read Out in Q4
Structure Therapeutics kept its fourth-quarter 2026 schedule for four pipeline events. The company will report data from a 44-week body fat study, a 30-week type 2 diabetes study, and the 12-week SWITCH maintenance trial for aleniglipron, while also starting a Phase 1 trial for its second amylin pill, ACCG-3535.
💲 Other KPIs
Unpaid bills and accrued clinical costs rose 64.3% from last quarter to $104.3 million by our math. Accounts payable — bills due to vendors — tripled from $11.1 million in June to $33.9 million in September, which kept third-quarter cash burn lower than the operating loss.
Interest earned on the cash balance rose 43.6% from a year ago, when the biotech group held less cash, but fell from $12.7 million in the second quarter and $13.6 million in the first quarter as cash balances declined.
Non-cash stock pay for employees rose 69.3% from $7.5 million a year ago and edged up from $12.6 million in the second quarter as the drugmaker hired staff for its clinical trials.
🔮 Guidance
Unchanged. Structure Therapeutics still expects its $1.24 billion in cash and short-term investments to fund operations and Phase 3 aleniglipron trials through the end of 2028. By our math, that leaves an average burn of at most $137.8 million per quarter over the next nine quarters, and the forecast excludes commercial manufacturing costs.
New. The US company expects topline results from both ACCOMPLISH-1 and ACCOMPLISH-2 in the second half of 2028, which lines up with the end of its projected cash runway.
New. After starting the 12-week multi-dose study of its oral amylin drug in the third quarter, the biotech firm plans to report topline weight-loss and safety data in the first half of 2027.
Pushed back. The clinical trial combining an oral amylin drug with an oral GLP-1 drug is now planned for 2027, later than the fourth-quarter 2026 target given in previous quarters.
❓ Key Questions
How much will commercial manufacturing cost before 2028?
The cash runway through 2028 leaves out commercial manufacturing and pre-launch work, even though management is already building commercial readiness plans for aleniglipron.
Why did the oral combination trial move to 2027?
In the second quarter, the company planned to start combining aleniglipron and ACCG-2671 in the fourth quarter of 2026; investors need to know if formulation or dosing caused the shift.
What was the placebo-adjusted weight loss at 72 weeks?
The extension study reported a 16.2% average weight reduction for the 180 mg group, but because it was an open-label extension, no placebo comparison was provided.